Leucovorin has suddenly become one of the internet’s most-searched medicines. The reason is not a new wonder drug launch, but a regulatory clarification that landed in the middle of a very public autism debate.
On March 10, 2026, the US Food and Drug Administration approved expanded use of leucovorin calcium tablets for people with cerebral folate transport deficiency caused by confirmed FOLR1 gene variants.
The approval was narrower than the public conversation around it. The FDA approval was for a rare FOLR1-related disorder that can involve developmental delay and autistic features in some patients, but not for autism as a general indication
It is the first FDA-approved treatment for that ultra-rare condition. More importantly, the agency did not approve leucovorin as a treatment for autism more broadly. For months, leucovorin had been circulating in public discussion as a possible therapy for autism after several small studies suggested potential benefits in selected groups of children. Some officials had previously highlighted the drug as promising, fuelling public interest and speculation.
So what exactly is leucovorin? Why has an old drug used in cancer care become part of an autism conversation? And what does it actually do inside the body? Here is what to know.
What is Leucovorin, exactly?
Leucovorin is also called folinic acid. It is a biologically active form of folate that can participate directly in cellular metabolic pathways.
While folate is Vitamin B9, calling it “just a vitamin” is misleading. It sits in folate metabolism in a way that gives it drug-like therapeutic uses. Its established uses include:
- Methotrexate rescue therapy, where leucovorin helps protect healthy cells after exposure to the chemotherapy drug methotrexate
- Enhancing the effect of fluorouracil chemotherapy, improving its anti-cancer activity in certain cancer regimens
- Treating overdose or toxicity from folic acid antagonists
As of March 2026, the FDA has now approved expanded use for cerebral folate transport deficiency in adults and children with confirmed FOLR1 variants.
This rare disorder affects the body’s ability to move folate into the brain. Folate is critical for normal brain development and neurological function. When transport is disrupted, children may develop a range of neurological symptoms such as:
- Developmental delay
- Movement disorders
- Seizures
- Cognitive impairment
- Behavioural changes, sometimes resembling autism
How Does Leucovorin Work?
Folate is essential for several biochemical processes, particularly those involved in DNA synthesis, amino acid metabolism and methylation reactions that regulate gene activity
In many metabolic pathways, folate must first be converted into active reduced forms before it can participate in these reactions.
Leucovorin is a reduced folate that can bypass some metabolic steps required by folic acid. In clinical practice, that is why it can “rescue” normal cells after exposure to folate antagonists such as methotrexate. It helps restore folate-dependent biochemical pathways needed for DNA synthesis and cell function.
In cerebral folate transport deficiency, the core problem is that folate is not being transported into the brain properly. The FDA describes the condition as one that disrupts folate delivery into the brain, which is critical for brain health. In this case, leucovorin may help compensate for that disruption by providing a biologically usable form of folate.
Researchers have been interested in whether some autistic children may have folate pathway abnormalities, including folate receptor alpha autoantibodies, that could impair folate transport to the brain. This is one reason leucovorin entered autism research.
Leucovorin in Autism Research
Autism research increasingly recognises that the condition is not a single biological entity. Instead, it likely represents a spectrum of overlapping mechanisms. Researchers have been trying to identify subgroups with treatable metabolic or immune-related features.
One hypothesis is that in some children, abnormal folate transport or folate receptor alpha autoantibodies may contribute to symptoms or language difficulties. These antibodies can interfere with folate transport across the blood-brain barrier, potentially affecting neurological development.
This observation led researchers to explore whether leucovorin might help improve neurological function in these specific subgroups of patients with underlying folate pathway abnormalities.
What Do The Studies Show?
Promising findings:
- A 2018 randomised placebo-controlled trial reported that high-dose folinic acid improved verbal communication over 12 weeks in children with autism and language impairment, with stronger effects in participants who were positive for folate receptor alpha autoantibodies (FRAA).
- A 2021 systematic review and meta-analysis concluded that leucovorin appeared associated with improvements in communication and some core and associated autism symptoms, though the authors also said further studies were needed to confirm and expand on the findings.
- A 2025 Chinese trial also explored high-dose folinic acid in autistic children and looked at possible links with folate metabolism gene polymorphisms, reflecting growing interest in whether some subgroups may respond differently.
The evidence base is still small. Studies differ in dose, patient selection, biomarkers, and endpoints. One trial was later retracted in January 2026, which weakens confidence in the overall literature and highlights the need for more rigorous research before firm conclusions can be drawn.
That is one reason
So Can Leucovorin Treat Autism?
At present, no regulatory authority has approved leucovorin as a treatment for autism itself. the The FDA did not extend approval to autism broadly, and the American Academy of Pediatrics do not recommend routine use of leucovorin for autism.
In clinical practice, some physicians may prescribe leucovorin off-label in carefully selected cases, particularly when laboratory evidence suggests abnormalities in folate pathways. However, off-label use does not mean the drug has been proven effective for autism across the broader population.
The Bottom Line
Leucovorin is already well established in oncology and chemotherapy support – and now, it has a new FDA-approved role in a rare folate transport disorder affecting the brain.
But while some research suggests leucovorin may help certain individuals with autism-related metabolic abnormalities, the broader evidence is still evolving. While it is not a miracle autism drug, its sudden rise in public attention reflects how an old, established drug can re-enter the spotlight when research discovers new pathways and intersects with new regulatory decisions.
